55
Participants
Start Date
November 16, 2022
Primary Completion Date
June 1, 2026
Study Completion Date
June 1, 2027
Retifanlimab
Administered 500mg IV on day 1 of every 28-day cycle, continued until disease progression, unacceptable toxicity, or 2 years from the first dose of study medication, whichever occurs first.
All-trans retinoic acid
All-trans retinoic acid (ATRA) 45mg/m2 orally in two equally divided doses on days 1-14 of each 28-day cycle, continued until disease progression, unacceptable toxicity, or 2 years from the first dose of study medication, whichever occurs first.
RECRUITING
University of Pennsylvania, Philadelphia
Collaborators (1)
Incyte Corporation
INDUSTRY
University of Pennsylvania
OTHER
Stephen Bagley, MD, MSCE
OTHER